However, as insurers continue implementing specialty-tier pricing, utilization management restrictions, and coverage limitations, consumers are likely to face ongoing challenges accessing affordable GLP-1 therapy
[8] [9] The FDA has approved specific formulations for diabetes management and others for chronic weight management in adults with obesity or overweight with weight-related comorbidities
81401852), the Natural Science Foundation of Shanghai (No
Candidates typically include adults with a Body Mass Index (BMI) of 30 or higher, classified as obese, or those with a BMI of 27 or higher who also face weight-related health challenges such as hypertension, type 2 diabetes, or dyslipidemia
That kind of caloric deficit drives weight loss, but your body does not exclusively burn fat stores for energy
Obstructive sleep apnea (OSA) is not on the CMS Bridge eligibility list